An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma

Trial Profile

An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 14 Dec 2014 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 18 Aug 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top